NGS Panels in Management of Myeloid-related Diseases
On June 13th, 2019, IPBA had the honor and pleasure to lead a workshop to evaluate the current state of play for molecular diagnostics from myeloid-related diseases in Europe and to explore the opportunities for the use of next generation sequencing (NGS) to better support patient care. Ten leading hematologists and hematopathologists were gathered, representing multiple European countries, who not only particpate in clinical studies and research but are involved in routine diagnostics and therapy.
Interactive sessions, punctuated with lively debate, provided much insights on key points for adoption of NGS in routine myeloid and MRD diagnostics like reimbursement, turn-around-time and consensus on genes there should be present on an actionable panel. Though there were many inter- and intra-country differences highlighted in experience, and opinion, some consenus was generated for what are the main issues and requirements for wider NGS adoption in the management for myeloid malignancies.
Workshop participants greatly appreciated the opportunity to discuss these vital issues and brainstorm on how to improve the diagnostics options for their myeloid patients and are already looking forward to a planned follow-up workshop at the American Society of Hematology (ASH) in December, 2019 in Orlando, Florida, USA, with leading specialists in the myeloid field from Europe, Asia and the Americas.
Please, do not hesitate to connect with us if you would like to learn more about the EHA wokshop outcomes, to take part on our next myeloid workshop at EHA or to understand how IPBA can help you with your diagnostics strategy and implementation in the myeloid magnancies space.
Julia Berges, PhD
Head of Market Analysis, Inflection Point Biomedical Advisors